Oncternal Therapeutics, Inc
Oncternal Therapeutics is a clinical-stage oncology company dedicated to developing innovative treatments for hematological malignancies and prostate cancer. Their scientific approach focuses on untapped biological pathways implicated in cancer generation or progression, aiming to bring first-in-class therapies to patients with critical unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Oncternal Therapeutics, Inc
12230 El Camino Real, Suite 230, San Diego, CA 92130
Patents
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US-12128026-B2
View DetailsSelective androgen receptor degrader (SARD) ligands and methods of use thereof
US-11591290-B2
View DetailsSelective androgen receptor degrader (SARD) ligands and methods of use thereof
US-11273147-B2
View Details
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US-12128026-B2
View DetailsSelective androgen receptor degrader (SARD) ligands and methods of use thereof
US-11591290-B2
View DetailsSelective androgen receptor degrader (SARD) ligands and methods of use thereof
US-11273147-B2
View DetailsProducts
ONCT-808
An autologous CAR T cell therapy candidate targeting a tumor-associated surface protein (ROR1) developed for treatment of hematologic and selected solid malignancies; in Phase 1/2 clinical development.
ONCT-534
A dual-action androgen receptor inhibitor small-molecule program (DAARI) developed as a targeted therapy for advanced, treatment-resistant prostate cancer; reported to have completed IND-enabling studies.
Zilovertamab
A monoclonal antibody therapeutic candidate that binds and inhibits a tumor-associated surface protein (ROR1) being developed for multiple hematologic and solid malignancies.
ONCT-808
An autologous CAR T cell therapy candidate targeting a tumor-associated surface protein (ROR1) developed for treatment of hematologic and selected solid malignancies; in Phase 1/2 clinical development.
ONCT-534
A dual-action androgen receptor inhibitor small-molecule program (DAARI) developed as a targeted therapy for advanced, treatment-resistant prostate cancer; reported to have completed IND-enabling studies.
Zilovertamab
A monoclonal antibody therapeutic candidate that binds and inhibits a tumor-associated surface protein (ROR1) being developed for multiple hematologic and solid malignancies.
Services
Design and conduct of sponsor-initiated and investigator-sponsored clinical studies in oncology, with public registry listings.
In-house preclinical research to support IND-enabling packages for small molecules and biologics, including medicinal chemistry and biological evaluation.
Assessment of requests for pre-approval access to investigational medicines using defined clinical and regulatory criteria.
Design and conduct of sponsor-initiated and investigator-sponsored clinical studies in oncology, with public registry listings.
In-house preclinical research to support IND-enabling packages for small molecules and biologics, including medicinal chemistry and biological evaluation.
Assessment of requests for pre-approval access to investigational medicines using defined clinical and regulatory criteria.
Expertise Areas
- Clinical trial management (early-phase oncology)
- Cell therapy development (CAR T and CAR-NK)
- Monoclonal antibody therapeutics
- Small-molecule drug discovery for resistant prostate cancer
Key Technologies
- Autologous CAR T cell therapy
- CAR-engineered NK and T cells
- Monoclonal antibody therapeutics
- Small-molecule androgen receptor degraders
News & Updates
On March 2025, Oncternal announced its intention to delist from Nasdaq and deregister with the SEC.
On September 12, 2024, Oncternal announced it was discontinuing its clinical trials and exploring strategic alternatives.
A study published in 2012 indicating that ROR1 is expressed in various human cancers.
Preclinical studies on ROR1-targeting CAR-T cells for solid tumors.
Research on new compounds with activity against enzalutamide-resistant prostate cancer.
A review of the WNT/ROR pathway in cancer and therapeutic strategies.
On March 2025, Oncternal announced its intention to delist from Nasdaq and deregister with the SEC.
On September 12, 2024, Oncternal announced it was discontinuing its clinical trials and exploring strategic alternatives.
A study published in 2012 indicating that ROR1 is expressed in various human cancers.
Preclinical studies on ROR1-targeting CAR-T cells for solid tumors.
Research on new compounds with activity against enzalutamide-resistant prostate cancer.
A review of the WNT/ROR pathway in cancer and therapeutic strategies.